Biomarkers of Renal Diseases
This book provides important and updated information on current research devoted to urinary biomarkers. Urinary biomarkers are characteristics that can be objectively measured and evaluated as indicators of normal biological or pathogenic processes of pharmacological responses to therapeutic interve...
Saved in:
| Other Authors: | , |
|---|---|
| Format: | Electronic Book Chapter |
| Language: | English |
| Published: |
Basel, Switzerland
MDPI - Multidisciplinary Digital Publishing Institute
2021
|
| Subjects: | |
| Online Access: | DOAB: download the publication DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000naaaa2200000uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_68315 | ||
| 005 | 20210501 | ||
| 003 | oapen | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 20210501s2021 xx |||||o ||| 0|eng d | ||
| 020 | |a books978-3-03943-912-6 | ||
| 020 | |a 9783039439119 | ||
| 020 | |a 9783039439126 | ||
| 040 | |a oapen |c oapen | ||
| 024 | 7 | |a 10.3390/books978-3-03943-912-6 |c doi | |
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a M |2 bicssc | |
| 100 | 1 | |a García-Estañ, Joaquín |4 edt | |
| 700 | 1 | |a Vargas, Felix |4 edt | |
| 700 | 1 | |a García-Estañ, Joaquín |4 oth | |
| 700 | 1 | |a Vargas, Felix |4 oth | |
| 245 | 1 | 0 | |a Biomarkers of Renal Diseases |
| 260 | |a Basel, Switzerland |b MDPI - Multidisciplinary Digital Publishing Institute |c 2021 | ||
| 300 | |a 1 electronic resource (276 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a This book provides important and updated information on current research devoted to urinary biomarkers. Urinary biomarkers are characteristics that can be objectively measured and evaluated as indicators of normal biological or pathogenic processes of pharmacological responses to therapeutic intervention. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Medicine |2 bicssc | |
| 653 | |a poststreptococcal acute glomerulonephritis | ||
| 653 | |a infection-related glomerulonephritis | ||
| 653 | |a nephritis-associated plasmin receptor | ||
| 653 | |a plasmin | ||
| 653 | |a acute kidney injury | ||
| 653 | |a renal biomarkers | ||
| 653 | |a furosemide stress test | ||
| 653 | |a functional assessment | ||
| 653 | |a urine | ||
| 653 | |a diabetic kidney disease | ||
| 653 | |a kidney function | ||
| 653 | |a proteomics | ||
| 653 | |a mass spectrometry | ||
| 653 | |a statistical clinical model | ||
| 653 | |a machine learning | ||
| 653 | |a acute tubulointerstitial nephritis | ||
| 653 | |a immunology | ||
| 653 | |a biomarkers | ||
| 653 | |a chronic kidney disease | ||
| 653 | |a differential diagnosis | ||
| 653 | |a label-free quantification | ||
| 653 | |a renal transplant | ||
| 653 | |a extracellular vesicles | ||
| 653 | |a acute rejection | ||
| 653 | |a chronic rejection | ||
| 653 | |a chronic allograft dysfunction | ||
| 653 | |a calcineurin-inhibitor nephrotoxicity | ||
| 653 | |a Polyomavirus associated nephropathy | ||
| 653 | |a immunosuppression | ||
| 653 | |a upper urinary tract obstruction | ||
| 653 | |a kidney injury | ||
| 653 | |a neutrophil gelatinase-associated lipocalin | ||
| 653 | |a monocyte chemotactic protein-1 | ||
| 653 | |a kidney injury molecule 1 | ||
| 653 | |a cystatin C | ||
| 653 | |a vanin-1 | ||
| 653 | |a microRNA | ||
| 653 | |a uromodulin | ||
| 653 | |a kidney graft function | ||
| 653 | |a biomarker | ||
| 653 | |a kidney transplantation | ||
| 653 | |a long noncoding RNA | ||
| 653 | |a rejection | ||
| 653 | |a microvascular injury | ||
| 653 | |a urinary aminopeptidases | ||
| 653 | |a arterial hypertension | ||
| 653 | |a renal function | ||
| 653 | |a urinary biomarkers | ||
| 653 | |a markers of AKI | ||
| 653 | |a cystatin-C | ||
| 653 | |a NGAL | ||
| 653 | |a KIM-1 | ||
| 653 | |a exercise | ||
| 653 | |a end-stage kidney disease (ESKD) | ||
| 653 | |a cardiovascular disease | ||
| 653 | |a epidemiology | ||
| 653 | |a CKD | ||
| 653 | |a macrophage subpopulation | ||
| 653 | |a renal fibrosis | ||
| 653 | |a trichostatin A | ||
| 653 | |a kidney graft | ||
| 653 | |a T-cell-mediated rejection | ||
| 653 | |a antibody-mediated rejection | ||
| 653 | |a diagnostic test accuracy | ||
| 653 | |a gentamicin | ||
| 653 | |a sepsis | ||
| 653 | |a miRNA | ||
| 653 | |a nephrotoxicity | ||
| 653 | |a vancomycin | ||
| 653 | |a n/a | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/3325 |7 0 |z DOAB: download the publication |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/68315 |7 0 |z DOAB: description of the publication |